Key facts
- BTB Therapeutics’s last known valuation is $13.0M (Nov 2025).
- It has raised $7.7M across 2 recorded rounds; the latest was Seed Round ($3.4M) in Nov 2025.
- Notable investors include SMBC Venture Capital, Kyoto University Innovation Capital, Kyoto Capital Partners (Japan).
- BTB Therapeutics has filed 1 Form D with the SEC, most recently Feb 2025 ($3.3M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for BTB Therapeutics
Funding rounds
2 roundsAbout BTB Therapeutics
Developer of non-opioid medicine intended to use small-molecule compounds targeting RNA splicing for the treatment of diseases and cancer immunotherapy. The company utilizes a novel mechanism of action that promotes the secretion of endogenous opioids and offers a therapeutic drug for rare congenital diseases caused by abnormal splicing, helping the medical industry to reduce illness, save people, and lead to a harmonious society.
- Sector
- Healthcare
- HQ
- Escondido, CA, United States
- Founded
- 2020
- Employees
- 5
- Website
- btbtherapeutics.com/
- Ownership
- Privately Held (backing)
BTB Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BTB Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BTB Therapeutics in its N-PORT filings yet. We sweep new filings monthly.